Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma

Yaya Chu; Aliza Gardenswartz; Amanda M. Termuhlen; Mitchell S. Cairo

doi:10.1111/bjh.15753

Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma

Yaya Chu, Aliza Gardenswartz, Amanda M. Termuhlen, Mitchell S. Cairo

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

Patients with relapsed, refractory or advanced stage B non-Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high-risk populations, including haematopoietic stem cell transplant, bispecific antibodies, viral-derived cytotoxic T cells, chimeric antigen receptor (CAR) T cells, and natural killer (NK) cell therapy, as discussed at the 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma on September 26th–29th 2018 in Rotterdam, the Netherlands, and explores the future of NK/CAR NK therapies.

Original language	English (US)
Pages (from-to)	1055-1070
Number of pages	16
Journal	British journal of haematology
Volume	185
Issue number	6
DOIs	https://doi.org/10.1111/bjh.15753
State	Published - Jun 2019

Bibliographical note

Funding Information:
Supported in part by grants from Pediatric Cancer Research Foundation (MSC), St. Baldrick’s Foundation (MSC), New York Medical College School of Medicine Translational Science Institute Children Health Translational Research Award (YC), National Cancer Institute (MSC) (1R13CA232383-01) and National Heart, Lung and Blood Institute (MSC) (1R13CA232383-01).

Publisher Copyright:
© 2019 British Society for Haematology and John Wiley & Sons Ltd

Keywords

B-cell non-Hodgkin lymphoma
IL-15 superagonist
cellular immunotherapy
chimeric antigen receptor
stem cell transplantation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1111/bjh.15753

Find It

Find It at U of M Libraries

Cite this

Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma. / Chu, Yaya; Gardenswartz, Aliza; Termuhlen, Amanda M. et al.
In: British journal of haematology, Vol. 185, No. 6, 06.2019, p. 1055-1070.

Research output: Contribution to journal › Review article › peer-review

@article{5bb429177033480aac7b1f7491d8f202,

title = "Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma",

abstract = "Patients with relapsed, refractory or advanced stage B non-Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high-risk populations, including haematopoietic stem cell transplant, bispecific antibodies, viral-derived cytotoxic T cells, chimeric antigen receptor (CAR) T cells, and natural killer (NK) cell therapy, as discussed at the 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma on September 26th–29th 2018 in Rotterdam, the Netherlands, and explores the future of NK/CAR NK therapies.",

keywords = "B-cell non-Hodgkin lymphoma, IL-15 superagonist, cellular immunotherapy, chimeric antigen receptor, stem cell transplantation",

author = "Yaya Chu and Aliza Gardenswartz and Termuhlen, {Amanda M.} and Cairo, {Mitchell S.}",

note = "Funding Information: Supported in part by grants from Pediatric Cancer Research Foundation (MSC), St. Baldrick{\textquoteright}s Foundation (MSC), New York Medical College School of Medicine Translational Science Institute Children Health Translational Research Award (YC), National Cancer Institute (MSC) (1R13CA232383-01) and National Heart, Lung and Blood Institute (MSC) (1R13CA232383-01). Publisher Copyright: {\textcopyright} 2019 British Society for Haematology and John Wiley & Sons Ltd",

year = "2019",

month = jun,

doi = "10.1111/bjh.15753",

language = "English (US)",

volume = "185",

pages = "1055--1070",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc.",

number = "6",

}

TY - JOUR

T1 - Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma

AU - Chu, Yaya

AU - Gardenswartz, Aliza

AU - Termuhlen, Amanda M.

AU - Cairo, Mitchell S.

N1 - Funding Information: Supported in part by grants from Pediatric Cancer Research Foundation (MSC), St. Baldrick’s Foundation (MSC), New York Medical College School of Medicine Translational Science Institute Children Health Translational Research Award (YC), National Cancer Institute (MSC) (1R13CA232383-01) and National Heart, Lung and Blood Institute (MSC) (1R13CA232383-01). Publisher Copyright: © 2019 British Society for Haematology and John Wiley & Sons Ltd

PY - 2019/6

Y1 - 2019/6

N2 - Patients with relapsed, refractory or advanced stage B non-Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high-risk populations, including haematopoietic stem cell transplant, bispecific antibodies, viral-derived cytotoxic T cells, chimeric antigen receptor (CAR) T cells, and natural killer (NK) cell therapy, as discussed at the 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma on September 26th–29th 2018 in Rotterdam, the Netherlands, and explores the future of NK/CAR NK therapies.

AB - Patients with relapsed, refractory or advanced stage B non-Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high-risk populations, including haematopoietic stem cell transplant, bispecific antibodies, viral-derived cytotoxic T cells, chimeric antigen receptor (CAR) T cells, and natural killer (NK) cell therapy, as discussed at the 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma on September 26th–29th 2018 in Rotterdam, the Netherlands, and explores the future of NK/CAR NK therapies.

KW - B-cell non-Hodgkin lymphoma

KW - IL-15 superagonist

KW - cellular immunotherapy

KW - chimeric antigen receptor

KW - stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=85059561682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059561682&partnerID=8YFLogxK

U2 - 10.1111/bjh.15753

DO - 10.1111/bjh.15753

M3 - Review article

C2 - 30613939

AN - SCOPUS:85059561682

SN - 0007-1048

VL - 185

SP - 1055

EP - 1070

JO - British journal of haematology

JF - British journal of haematology

IS - 6

ER -

Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this